What DMSO Is Actually Used For—and Where the Evidence Falls Short

Carla Voss 2026-08-14

The short answer: what is DMSO used for in humans?

DMSO—dimethyl sulfoxide—has one narrow, established role as an active treatment in the United States: purified prescription DMSO is placed directly into the bladder to relieve symptoms of interstitial cystitis. The U.S. product is called Rimso-50, and a healthcare professional administers it rather than applying it to the skin or giving it by mouth. The treatment is intended to relieve symptoms, not cure interstitial cystitis (Mayo Clinic’s intravesical DMSO monograph).

That status applies to a specific prescription product, route, and indication. It does not mean that DMSO generally is approved for treating disease, nor does it validate nonprescription creams, gels, oral products, veterinary preparations, or industrial solvents as treatments for pain or other conditions.

DMSO appears in medicine and biomedicine in four distinct roles:

Approved active treatment: prescription DMSO instilled into the bladder for symptoms of interstitial cystitis.
Investigated or medically supervised use: experimental, historical, or off-label applications in pain care, dermatology, wound care, and other settings.
Carrier or formulation ingredient: DMSO helps another substance remain dissolved or cross a biological barrier.
Cryoprotectant: DMSO helps protect cells and other biological materials during freezing and storage.

Only the first category represents the established U.S. disease-treatment indication discussed here. The other roles may be legitimate in research, pharmaceutical formulation, biological-material processing, or specialist care, but they do not demonstrate that DMSO independently treats arthritis, sports injuries, scars, burns, infections, headaches, eye disorders, scleroderma, or cancer.

Evidence snapshot

Use or function	Route or setting	DMSO’s role	Evidence status	Key concern
Interstitial-cystitis symptom relief	Direct bladder instillation	Active prescription treatment	Identified as the FDA-approved human indication	Clinician administration; symptom relief is not a cure
Knee osteoarthritis or general pain	Topical	Proposed active treatment	Mixed, methodologically weak evidence	Uncertain benefit, concentration, duration, and long-term safety
Delivery of another medicine	Usually a topical formulation	Carrier or penetration enhancer	Documented formulation function	Benefit may come from the other drug; unintended substances may also penetrate
Stem-cell storage	Controlled processing and storage	Cryoprotectant	Documented biomedical function	Preservation is not treatment of disease in a patient
Dermatology, wounds, extravasation injury, shingles-related treatment, or complex regional pain syndrome	Usually topical and medically supervised	Active ingredient, carrier, or part of a combination	Limited, historical, secondary, or confounded evidence	Outcomes cannot necessarily be attributed to DMSO alone
Cancer, scars, infections, headaches, eye disorders, burns, or sports injuries	Topical, oral, or other promoted routes	Claimed active treatment	Unsupported or insufficiently supported	Adverse effects, contamination, and delayed effective care

The practical answer for someone researching DMSO uses for humans is therefore narrower than online claim lists suggest. DMSO has a prescription bladder use and genuine technical functions in medicine and biomedicine, but it is not an established multipurpose home remedy.

What DMSO is and why it has so many proposed uses

DMSO is a sulfur-containing compound and a colorless, water-miscible solvent. It is derived as a by-product of wood-pulp processing and has a history of industrial and laboratory use.

Its defining property is its ability to cross biological barriers. DMSO readily penetrates skin, mucous membranes, and cell membranes. It can also affect barrier permeability and improve the solubility of another compound, helping that compound move with it. A dermatology review describes DMSO as both a solvent and a penetration enhancer, including through effects on the skin’s outer layer and on drug solubility (review of DMSO chemistry and dermatologic uses).

That penetration is useful in some controlled settings. A pharmaceutical formulation may use DMSO to help an active medicine reach tissue. Researchers use it to dissolve compounds that do not readily dissolve in water. Laboratories and clinical-processing facilities use it when preserving cells. Intravesical treatment takes advantage of its ability to enter the bladder lining.

The same property creates risk. DMSO does not necessarily distinguish between an intended medicine and an unintended chemical. Topical exposure may increase absorption of substances in a formulation or on the skin, including medication residues and contaminants. Cleaning an application area may remove some surface material, but it cannot certify the product, eliminate every residue, or resolve uncertain concentration and interaction risks.

Four roles should not be conflated:

Active treatment: DMSO itself is intended to produce a therapeutic effect.
Carrier: DMSO helps another active medicine cross a barrier.
Solvent or formulation ingredient: DMSO dissolves or stabilizes another compound.
Cryoprotectant: DMSO helps limit cellular damage during freezing.

These roles answer different questions. If DMSO carries a pain medicine through the skin, that does not prove DMSO independently relieves pain. If it protects cells during storage, that does not prove it repairs tissue in a living person. If researchers use it to dissolve an anticancer compound, that does not make DMSO a cancer treatment.

DMSO is metabolized in part to dimethyl sulfide, a volatile sulfur compound. This helps explain the characteristic garlic- or oyster-like taste, breath, and body odor associated with exposure. The odor also matters in research: participants and investigators may be able to guess who received DMSO, weakening blinding in trials that rely on subjective outcomes such as reported pain.

The FDA-approved use: prescription DMSO for interstitial cystitis

Rimso-50 is a purified prescription DMSO solution used to relieve symptoms of interstitial cystitis, a condition also discussed within the broader category of bladder pain syndrome. This is intravesical treatment, meaning the medicine is placed inside the bladder.

A healthcare professional introduces the solution through a catheter or syringe. It remains in the bladder temporarily and is then expelled during urination. This procedure is fundamentally different from rubbing DMSO on the lower abdomen, swallowing it, or receiving it intravenously. Evidence and safety experience from one route should not be transferred automatically to another.

The goal is symptom relief. Interstitial cystitis is not the only possible cause of bladder or pelvic pain, so prescription DMSO should not be viewed as a general treatment for every painful urinary or pelvic condition. Diagnosis, treatment selection, administration, and follow-up belong in clinical care.

Evidence may also differ by disease subtype. A 2023 review reported that the apparent effectiveness of intravesical DMSO was concentrated in Hunner-type interstitial cystitis. That narrower finding should not be generalized to every form of interstitial cystitis or bladder pain syndrome (2023 review of DMSO for interstitial cystitis and bladder pain syndrome).

Proposed explanations include anti-inflammatory activity and the scavenging of reactive molecules that may contribute to tissue damage. DMSO can penetrate the bladder mucosa and reach deeper layers. These mechanisms remain incompletely understood, however, and their plausibility does not prove that DMSO works for unrelated inflammatory or painful disorders.

Effects associated with bladder instillation can include discomfort during administration and a garlic-like taste, breath, or skin odor. Because some DMSO is absorbed and metabolized after instillation, effects outside the bladder area can occur.

Nothing about this clinical procedure supplies a do-it-yourself protocol. Professional drug information describes prescription, clinician-managed use; it does not establish a safe dose for topical, oral, intravenous, or improvised intravesical use.

Topical DMSO for arthritis and pain: what the trials show

Knee osteoarthritis is the best-developed example of the difference between a use being studied and being established. Topical DMSO has been tested in randomized trials, and some individual results appeared favorable. The overall evidence, however, has not been sufficiently consistent or rigorous to establish DMSO as an effective osteoarthritis treatment.

A 2008 systematic review included four randomized DMSO trials involving knee osteoarthritis. Two reported significant pain improvements relative to comparator treatments. Other trials found that DMSO did not outperform placebo, including studies using different concentrations or formulations. The reviewers concluded that no definitive determination of efficacy or safety could be made (systematic review in Osteoarthritis and Cartilage).

Several limitations reduce confidence in the apparently positive findings:

Few trials: A small evidence base is more vulnerable to chance, publication bias, and the influence of a single unusual result.
Inconsistent concentrations: The studies did not test one standardized DMSO preparation.
Short treatment periods: Brief studies cannot establish durable benefit or long-term safety.
Uncertain dosing: An optimal topical concentration had not been established before the treatments were compared.
Methodological weaknesses: Some studies had design or analysis problems that made their findings difficult to interpret.
Possible unblinding: DMSO’s recognizable odor and taste could reveal treatment assignment.
Subjective outcomes: Pain ratings are important, but expectations can affect them when participants suspect which treatment they received.

Blinding is particularly important in a pain trial. A placebo-controlled study works best when participants cannot identify the active product. If one preparation produces garlic-like breath or body odor, participants may infer their assignment.

A later pooled analysis suggested a small reduction in knee pain, but it combined studies of DMSO with studies of methylsulfonylmethane, or MSM. It included only a few trials and found significant variation among their results. Pooling two distinct substances cannot isolate DMSO’s independent effect.

The National Center for Complementary and Integrative Health similarly states that only a small amount of research has examined DMSO for osteoarthritis, so no conclusion can be reached about whether it helps. It also characterizes safety as uncertain because research is limited (NCCIH overview of DMSO and MSM for osteoarthritis).

Claims involving tendinitis, sprains, strains, bruises, muscle soreness, and other musculoskeletal pain have a less secure foundation. Some older trials or secondary summaries report possible benefits for selected conditions, while others report no meaningful difference. Variations in diagnosis, concentration, formulation, comparator, and study quality make broad conclusions inappropriate.

The available research does not establish:

that topical DMSO is a reliable general pain reliever;
an optimal concentration for osteoarthritis or sports injuries;
how frequently it should be applied;
how long treatment could continue safely;
whether benefits outweigh risks for a particular patient; or
a universally safe self-treatment regimen.

Mixed results do not prove that DMSO can never help an individual. They mean that the evidence cannot reliably distinguish a genuine treatment effect from placebo effects, bias, inconsistent dosing, and random variation. The principal systematic review also searched literature only through November 2007, which should be kept in mind when interpreting its conclusions.

Other medical and biomedical roles: carrier, cryoprotectant, and investigational treatment

DMSO can have a legitimate role in a treatment or biomedical process without being the ingredient principally responsible for clinical improvement.

Carrier and formulation solvent

As a penetration enhancer, DMSO may be included in a formulation to help another medicine cross the skin. The other drug may provide the primary therapeutic effect, while DMSO changes its delivery. Researchers also use DMSO to dissolve compounds before testing them.

This distinction is especially important with combination therapies. If a treatment includes DMSO, another medication, removal of tissue, and a light-based procedure, a favorable outcome cannot show which component was responsible unless the study includes a suitable comparison designed to isolate DMSO’s contribution.

The same caution applies when DMSO is combined with an antiviral medicine, wound-care procedure, or treatment for tissue injury caused by an accidental chemotherapy leak. “A treatment containing DMSO produced a result” is not equivalent to “DMSO alone produced the result.”

Cryopreservation

DMSO is used as a cryoprotectant in controlled stem-cell and biological-material processing. DMSO helps reduce osmotic stress and cellular dehydration, supporting long-term stem-cell storage. A systematic review of human adverse reactions identifies stem-cell cryopreservation, interstitial-cystitis treatment, and drug penetration as principal medical or pharmaceutical contexts for DMSO (systematic review of adverse reactions to DMSO).

Cryopreservation is a genuine biomedical function, but it occurs while cells or other biological materials are being processed or stored. It is not evidence that applying or swallowing DMSO treats disease in a patient.

Investigational and medically supervised applications

DMSO has been investigated in dermatology, wound care, complex regional pain syndrome, shingles-related treatment, and tissue injury caused when certain chemotherapy drugs escape a vein. The evidence ranges from historical observations and small controlled trials to secondary summaries and combination treatments.

Some references describe possible effectiveness in selected applications. Broader critical assessments are less confident because the research may be sparse, dated, poorly controlled, or unable to separate DMSO from another intervention. These uses are better described as investigational, specialist-directed, historical, or insufficiently established—not as a list of validated home treatments.

Laboratory evidence

DMSO should not be assumed to be biologically inert simply because researchers use it as a solvent. In one laboratory experiment, exposing cultured human-derived cardiac and liver microtissues to 0.1% DMSO produced extensive molecular changes. That experiment demonstrated biological activity under laboratory conditions, but it did not establish clinical harm at ordinary patient exposures (Scientific Reports study of DMSO in human-derived microtissues).

The distinction works in both directions. Laboratory evidence of molecular activity does not by itself prove patient harm, just as test-tube evidence of antioxidant, antiviral, or anti-inflammatory activity does not prove clinical benefit.

Popular claims that go beyond the evidence

DMSO’s penetration, solvent properties, and long history have encouraged claims for many unrelated conditions. Proposed explanations often invoke anti-inflammatory, analgesic, antioxidant, or antiviral activity. Even when a mechanism is plausible, effectiveness must still be demonstrated in suitable human trials.

Myth or promoted claim	What the evidence supports
“DMSO treats cancer.”	There is no supporting clinical evidence that DMSO is an effective cancer treatment. Laboratory solvent use and combination procedures do not establish anticancer effectiveness in patients.
“It heals sprains, strains, tendinitis, and bruises.”	Some older studies reported possible improvements, but results are contradictory and controls are often weak. No dependable regimen has been established.
“It speeds healing of wounds and burns.”	Historical and small reports exist, but convincing evidence of independent benefit is lacking. Irritation and unintended chemical absorption are additional concerns.
“It removes scars.”	Scar and keloid applications have been discussed or investigated, but the evidence is too limited to establish effectiveness.
“It treats scleroderma or scleroderma ulcers.”	Older reports have not produced firm proof. Some secondary summaries classify topical DMSO as possibly ineffective for scleroderma.
“It relieves headaches.”	Promotion and anecdotal use are not supported by convincing controlled evidence. Headache has also been reported as an adverse effect.
“It treats cataracts, glaucoma, or retinal disease.”	Eye-treatment claims are unsupported. Eye symptoms require appropriate professional assessment rather than improvised DMSO use.
“It kills infections in the body.”	Laboratory effects against microorganisms do not establish an effective human treatment. Claims for skin infections and shingles are unsupported or complicated by combination therapy.

Cancer is the clearest boundary. Consumer medical references report no evidence that DMSO treats cancer and warn that relying on it could delay effective care (WebMD’s review of DMSO uses and risks). Substituting DMSO for diagnostic evaluation, surgery, radiation, systemic therapy, or other evidence-based treatment may cost critical time.

Wound, scar, and dermatology claims require more nuance. Older reviews sometimes describe promising findings involving pressure ulcers, ischemic wounds, scars, or chemotherapy-extravasation injuries. Many reports, however, used small samples, weak controls, historical case series, or combinations of DMSO with another medicine or procedure. Such findings may support further research or specialist consideration without justifying routine consumer use.

The same evidentiary standard applies to anti-inflammatory, antiviral, antioxidant, or pain-blocking explanations. A proposed action is not a demonstrated health outcome. Clinical benefit depends on whether a meaningful effect occurs in people, at a tolerable exposure, through the proposed route, and compared with an appropriate control.

Product purity does not close this evidence gap. Pharmaceutical purity may reduce the risk of exposure to unknown contaminants, but it cannot make an unsupported treatment effective. “Pure” answers a product-quality question; it does not establish clinical benefit.

Routes, product grades, and why they cannot be treated as interchangeable

DMSO’s effects and risks depend on where it goes, how much reaches the body, what accompanies it, and how long exposure continues. Evidence from one route cannot be generalized automatically to another.

Route or exposure	Typical context	Evidence status	Main distinction or concern
Intravesical	Prescription solution placed directly into the bladder	Established prescription context for interstitial-cystitis symptom relief	Clinician-administered, route-specific treatment
Topical	Nonprescription gels, creams, or medicated formulations	Uncertain for common pain claims	Absorption through skin, irritation, variable concentration, and transport of other substances
Oral	Consumer products or historical research	Safety and effectiveness unclear	No universal evidence-based consumer dose
Intravenous	Historical or investigational medical exposure	Not established for consumer self-treatment	Direct systemic exposure creates risks different from topical or bladder use
Laboratory or cryopreservation	Solvent use, cell processing, freezing, and storage	Documented technical function	Not administration intended to treat disease
Industrial or veterinary	Manufacturing, solvent, or animal-use product	Unsuitable for human use	Purity and contaminant profile may be unknown

Intravesical DMSO

This is the established prescription context. A professional places purified DMSO directly into the bladder for interstitial-cystitis symptom relief. Mayo Clinic identifies interstitial cystitis as the only FDA-approved human use and warns that industrial and veterinary preparations must not be used in humans because their purity is unknown.

A topical, veterinary, industrial, or laboratory product must not be substituted for the prescription bladder preparation.

Topical DMSO

DMSO is absorbed through skin and may increase penetration of other substances. Reported local effects include irritation, itching, burning, tingling, and dryness. Its effectiveness for common pain claims remains uncertain, and nonprescription products may vary substantially in concentration and formulation.

Availability is not proof of approval or effectiveness. A gel being sold online—and a percentage being prominently printed on its label—does not establish pharmaceutical quality, clinical benefit, or a safe treatment schedule.

Oral DMSO

Oral DMSO has appeared in historical research and consumer products, but its safety is unclear. Experience with topical or intravesical DMSO cannot be used to infer a safe oral exposure. No universal evidence-based consumer dose has been established.

Intravenous DMSO

Historical or investigational intravenous use does not make self-injection appropriate.

Published laboratory and historical literature has associated very high blood concentrations or direct intravenous exposure with effects including red-blood-cell damage, local irritation, and tissue injury. These reports do not define a simple universal threshold, but they demonstrate why route and concentration matter.

Laboratory and preservation exposure

When DMSO dissolves an experimental compound or protects frozen cells, it is performing a controlled technical function. That role should not be converted into a treatment claim for the person from whom cells were obtained or to whom they may later be administered.

Product grade and purity

Purified prescription DMSO is not interchangeable with industrial, veterinary, or casually sourced products. Unknown impurities are particularly concerning because DMSO crosses skin and mucous membranes. Industrial and veterinary products are unsuitable for human use.

Higher purity may reduce one hazard while leaving unresolved questions about effectiveness, concentration, interactions, co-exposures, and long-term safety.

Side effects, interactions, and who should seek medical guidance

DMSO safety cannot be reduced to a single description such as “safe” or “toxic.” Risk can vary with route, concentration, amount, duration, product purity, accompanying chemicals, concurrent medicines, and the user’s health.

Commonly reported effects

Reported effects across different routes include:

skin irritation, burning, itching, tingling, or dryness;
garlic- or oyster-like taste;
garlic-like breath or body odor;
digestive upset;
nausea, vomiting, diarrhea, or constipation;
headache;
dizziness;
drowsiness; and
reduced appetite.

These effects do not occur with every route or in every person. Conversely, an effect being common or temporary does not mean that every exposure is harmless.

A systematic review covering human adverse-reaction reports found that gastrointestinal and skin reactions were the most commonly described categories. The authors observed that reactions appeared more frequent at higher doses and often seemed mild and transient. The studies were highly heterogeneous, however, no meta-analysis was performed, and the review could not define a universally safe dose across routes and uses.

Symptoms requiring prompt evaluation

Breathing difficulty, hives, a widespread rash, marked itching, or swelling of the face may indicate a serious allergic reaction and require prompt medical evaluation. Mayo Clinic lists breathing difficulty, rash, hives, itching, and facial swelling among symptoms for which a patient receiving intravesical DMSO should seek medical attention.

For severe or rapidly worsening symptoms, or after an unintended exposure involving an unknown or nonhuman product, seek advice from an appropriate healthcare or emergency service rather than attempting to calculate safety from the product concentration alone.

Interaction concerns

Because DMSO can alter penetration and absorption, it may change exposure to other substances. Consumer medical references raise potential concerns involving:

anticoagulants and other medicines affecting bleeding;
sedatives;
steroids;
insulin;
topical medicines;
injected medicines; and
other oral prescription drugs.

The magnitude and clinical importance of these potential interactions are not well quantified. Interaction lists also differ among references, reflecting incomplete evidence rather than proof that interactions are absent. A consumer medical reference lists possible interactions involving topical, injected, and oral medications and advises caution with insulin and certain health conditions (RxList overview of DMSO precautions and interactions).

Someone taking prescription medicine should ask a clinician or pharmacist about the specific drug, DMSO product, route, and proposed use rather than relying on a generic interaction list.

Applying DMSO over another topical medicine is especially difficult to assess. It may alter how much medicine crosses the skin, and the result cannot be predicted safely from that medicine’s ordinary instructions.

People who need professional guidance

Limited safety evidence warrants particular caution during pregnancy and breastfeeding and for people with diabetes, asthma, blood disorders, or liver or kidney disease. These circumstances do not all create the same risk.

Anyone taking prescription medicine should disclose the exact product, route, concentration, and intended DMSO use to a clinician or pharmacist. Saying only that someone “uses DMSO” does not provide enough information for a useful assessment.

Contamination and product-quality risks

DMSO’s penetration-enhancing property makes contamination more than a surface-quality issue. Industrial and veterinary products are unsuitable for human use because their purity is not assured for that purpose.

Cleaning the skin may reduce some surface material, but it does not certify the DMSO product, eliminate every residue, or resolve uncertain dosing and interaction risks. It should not be treated as a guarantee of safe topical use.

No universal self-treatment regimen

There is no universal evidence-based dose, topical concentration, application frequency, or long-term schedule for nonprescription DMSO. There is likewise no established consumer oral dose that can be assumed safe and effective across conditions.

The practical boundaries are straightforward:

Prescription intravesical DMSO is a specific, clinician-administered option for interstitial-cystitis symptom relief.
Carrier and cryopreservation functions are legitimate but do not prove that DMSO treats disease.
Evidence for topical pain treatment remains mixed and insufficient.
Oral, intravenous, industrial, veterinary, and improvised uses should not be inferred from prescription bladder treatment.
Route, concentration, purity, co-exposures, medications, and health status can materially change risk.

This information can support a focused conversation with a healthcare professional, but it is not a do-it-yourself treatment protocol. DMSO should not replace supervised diagnosis or evidence-based care.

Frequently asked questions

Is DMSO FDA-approved for pain or arthritis?

No. DMSO is not identified as FDA-approved for general topical treatment of pain or arthritis. Its established U.S. indication is purified prescription DMSO placed into the bladder for relief of interstitial-cystitis symptoms.

Topical DMSO has been studied for knee osteoarthritis, but trials produced conflicting results and had methodological weaknesses. The evidence does not establish an optimal concentration, treatment duration, or long-term self-treatment regimen.

Are over-the-counter DMSO creams the same as prescription bladder DMSO?

No. Prescription bladder DMSO is a purified solution intended for intravesical administration by a healthcare professional. Over-the-counter creams and gels are topical products that may differ in concentration, ingredients, manufacturing controls, labeling, and intended route.

A product’s nonprescription availability does not make it approved for pain, arthritis, or another condition. A topical product must never be substituted for a prescribed bladder preparation or introduced into the bladder.

Can DMSO carry medicines or contaminants through the skin?

Yes. DMSO can increase skin penetration of some substances, which is why it can function as a drug-delivery carrier. The same property may increase exposure to unintended chemicals or contaminants in a formulation or on the skin.

That does not mean every surface substance will be absorbed to the same extent. It does mean that casual mixing and application are difficult to assess, and cleaning the skin cannot guarantee safety.

Why does DMSO cause garlic-like breath or body odor?

DMSO is metabolized in part to dimethyl sulfide, a volatile sulfur-containing compound. Its elimination helps produce the characteristic garlic- or oyster-like taste, breath, and body odor associated with DMSO exposure.

The recognizable odor can also affect research quality because participants may realize that they received active DMSO rather than placebo.

Are DMSO and MSM the same substance?

No. DMSO, or dimethyl sulfoxide, and MSM, or methylsulfonylmethane, are chemically related but distinct substances. DMSO functions as a solvent, penetration enhancer, cryoprotectant, and prescription intravesical treatment. MSM is commonly sold as a dietary supplement.

Evidence, doses, adverse effects, and safety conclusions for MSM cannot be transferred to DMSO—or vice versa. Research pooling the two may generate hypotheses, but it cannot establish DMSO’s independent effect. Readers comparing them can review the separate discussion of evidence on MSM supplements.